Melden Sie sich bitte kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Melden Sie sich bitte kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Alopecia areata
Baricitinib, Olumiant®, JAK1/2, Ritlecitinib, Litfulo®, JAK3/TEC
Atopische Dermatitis
Abrocitinib, Cibinqo®, JAK1, Baricitinib, Olumiant®, JAK1/2, Dupilumab, Dupixent®, IL-4/IL-13, Lebrikizumab, Ebglyss®, IL-13, Nemolizumab, Nemluvio®, IL-31RA, Tralokinumab, Adtralza®, Upadacitinib, Rinvoq®
Chronisch spontane Urtikaria
Omalizumab, Xolair®; Biosimilar: Omlyclo®, IgE
Chronisches Handekzem
Delgocitinib, Anzupgo 20 mg/g Creme, JAK1/2/3, TYK2
Generalisierte pustulöse Psoriasis
Spesolimab, Spevigo®, IL-36R
Hidradenitis suppurativa
Adalimumab, Humira®; Biosimilars: Amgevita®, Amsparity®, Hefiya®, Hukyndra®, Hulio®, Hyrimoz®, Idacio®, Imraldi®, Libmyris®, Yuflyma®, TNF-α, Bimekizumab, Bimzelx®, IL-17A/IL-17F/IL-17AF, Secukinumab, Cosentyx®, IL-17A
Plaque-Psoriasis
Adalimumab, Humira®; Biosimilars: Amgevita®, Amsparity®, Hefiya®, Hukyndra®, Hulio®, Hyrimoz®, Idacio®, Imraldi®, Libmyris®, Yuflyma®, TNF-α, Apremilast, Otezla®, PDE-4, Bimekizumab, Bimzelx®, IL-17A/IL-17F/IL-17AF, Brodalumab, Kyntheum®, IL-17RA, Certolizumab Pegol, Cimzia®, Deucravacitinib, Sotyktu®, TYK2, Etanercept, Enbrel®; Biosimilars: Benepali®, Erelzi®, Nepexto®, Guselkumab, Tremfya®, IL-23, Infliximab, Remicade®; Biosimilars: Flixabi®, Inflectra®, Remsima®, Zessly®, Ixekizumab, Taltz®, IL-17A, Risankizumab, Skyrizi®, Secukinumab, Cosentyx®, Tildrakizumab, Ilumetri®, Ustekinumab, Stelara®; Biosimilars: Eksunbi®, Otulfi®, Pyzchiva®, Steqeyma®, Uzpruvo®, Wezenla®, IL-12/IL-23
Prurigo nodularis
Dupilumab, Dupixent®, IL-4/IL-13, Nemolizumab, Nemluvio®, IL-31RA
Psoriasis-Arthritis
Abatacept, Orencia®, CTLA-4, Adalimumab, Humira®; Biosimilars: Amgevita®, Amsparity®, Hefiya®, Hukyndra®, Hulio®, Hyrimoz®, Idacio®, Imraldi®, Libmyris®, Yuflyma®, TNF-α, Apremilast, Otezla®, PDE-4, Bimekizumab, Bimzelx®, IL-17A/IL-17F/IL-17AF, Certolizumab Pegol, Cimzia®, Etanercept, Enbrel®; Biosimilars: Benepali®, Erelzi®, Nepexto®, Golimumab, Simponi®, Guselkumab, Tremfya®, IL-23, Infliximab, Remicade®; Biosimilars: Flixabi®, Inflectra®, Remsima®, Zessly®, Ixekizumab, Taltz®, IL-17A, Risankizumab, Skyrizi®, Secukinumab, Cosentyx®, Tofacitinib, Xeljanz®, JAK1/3, Upadacitinib, Rinvoq®, JAK1, Ustekinumab, Stelara®; Biosimilars: Eksunbi®, Otulfi®, Pyzchiva®, Steqeyma®, Uzpruvo®, Wezenla®, IL-12/IL-23
Vitiligo
Ruxolitinib, OpzeluraTM 15 mg/g Creme, JAK1/2
In Kooperation mit